Author Interviews, Cancer Research, UCSF / 03.04.2015
Signal Pathway Allows Lung Cancer Cells To Resist Chemotherapy
MedicalResearch.com Interview with:
Trever G. Bivona MD PhD
Assistant Professor, Hematology and Oncology
UCSF
Medical Research: What is the background for this study? What are the main findings?
Dr. Bivona: Resistance to targeted cancer therapy remains a problem in the treatment of cancer patients. These targeted drugs are often effective at shrinking the tumor, but do so incompletely. This incomplete response results in residual disease that is drug resistant and eventually grows to cause relapse that is lethal in patients. We investigated the mechanisms underlying this residual disease state in lung cancers treated with the EGFR targeted therapy Tarceva. We discovered that the tumor cells survival initial EGFR targeted therapy treatment by activating a signaling pathway called NF-kappa B. This NF-kappa B pathway then promotes tumor cell survival, residual disease, and eventual relapse in the lung cancer models we studied.
(more…)